Algernon Pharmaceuticals Announces Positive Trending Interim Data for its Phase 2b/3 Ifenprodil COVID Study
Company or
Algernon ) a clinical stage pharmaceutical development company, is pleased to report, in a descriptive format, positive trending interim data for the Phase 2b part of the Company s Phase 2b/3 clinical study of Ifenprodil for COVID-19.
For the endpoint of ventilation by day 15, there was a trend towards fewer patients requiring mechanical ventilation in the high dose Ifenprodil treatment arm, as compared to patients who were in the untreated arm of the study. Mechanical ventilation is associated with poor prognosis in COVID-19 patients, including increased risk of mortality and procedural complications.